3D printing is driving innovation and improving quality. By bridging the gap between the digital and the physical environments, innovative Life Science companies are accelerating the delivery of next generation products that are personalized, more precise and higher quality than ever before.

With the use of the latest technology, life science companies can break through barriers, using new methods of manufacturing processes, or using new materials to create unique offerings and can achieve market differentiation among competitors.

Axendia content is restricted for personal use only. Reproduction or distribution of Axendia content in any form without Axendia’s prior written permission is forbidden.

With 3D Printing and Virtual Human Modeling and Simulation, Life Science companies have the opportunity to innovate faster and with more confidence than ever before

By: Sandra K. Rodriguez, Market Analyst

SIMULIA is one of eleven brands at Dassault Systèmes. During their Analyst Day, company executives provided an overview of the brand’s simulation offerings under a common theme: Enabling end-to-end digital design to production processes by deploying all multiphysics simulation technologies to enable clients to start making parts and systems that work, faster.

Print to Perform

3D Printing, also referred to as Additive Manufacturing (AM) is a complex process. However, on the 3DEXPERIENCE platform, users can digitally accelerate AM while creating lightweight, yet functional generative designs. When moving from powder to working parts, there are significant challenges in the real-world process phase of AM. Using simulation for build planning, virtual printing, post-processing and heat treatment effects can optimize the build and ultimately save time by reducing errors and rework. With virtual printing, users can simulate not just a printing process but post-processing procedures and conduct in-service validation. Rather than relying on static documents and experience from expensive physical builds, establishing a digital thread from design to field performance unites all functionality and eliminates silos via a digital platform. SIMULIA’s Additive Manufacturing message is clear: Print to Perform.

Virtual Human Modeling

Karl D’Souza, Sr. Solution Consultant, SIMULIA Virtual Human Modeling at Dassault Systèmes, pointed out that simulation is widespread in the development of medical devices but that a lot more is possible. In particular, medical device companies are now creating more realistic models of the human body to understand how a product will perform in its intended environment. Continue reading →

Today, the goal of healthcare is improving diagnostics and patient outcomes. To this end, the healthcare ecosystem is undergoing a transformation aimed at improving the quality of care while simultaneously controlling costs. In simple terms, the model is shifting from sick-care to well-care.

The power of the Internet of Medical Things (IoMT) and advanced technologies are enabling businesses to think outside the box. In the case of Sysmex, the company went beyond just ‘building a better box’ in support of improved patient outcomes.

Learn how the company is disrupting the blood testing market in our latest IoMT Case Study, as we highlight:

Excessive focus on compliance can create hurdles in cultivating quality and innovation

By: Daniel R. Matlis, President

What is the role of Quality in MedTech? 10% said the primary role of quality is to drive product / process improvement. In sharp contrast, 85% indicated the primary role of quality is ensuring compliance

No wonder, the industry has to overcome some many hurdles when cultivating a culture of quality and innovation.

To compete in today’s global markets, Med-Tech companies must change their approach to Quality, from meeting compliance requirements, to driving product and process improvements across the product life-cycle.

A closed loop approach can help MedTech organizations make this crucial shift by enabling better collaboration, visibility and product quality across the product life-cycle.

Also significant were risks associated with geopolitical unrest and natural disasters (43%). At the time of the survey, Japan’s earthquake and tsunami were fresh in the memories of industry executives. More recently, Hurricane Maria quickly gained the attention of the FDA. Within 30 days of the storm making landfall in Puerto Rico, the agency identified 50 types of devices that it deemed critically important. The agency indicated in a press release that it was particularly concerned about the potential shortage of blood-related devices. Other current day geopolitical events affecting industry include Brexit, tensions on the Korean peninsula, and NAFTA re-negotiations that are far from being completed. Continue reading →

Research Corner

LSP Article Archives

LSP Article Archives

Connect With Us

Life-Science Panorama is Brought to you by Axendia, Inc. Copyright 2006-2018 Axendia, Inc. All Rights Reserved.
No Portion of this publication may be duplicated or redistributed in any form without approval from Axendia.